ArticleRSC advances2025
Synthesis of new Ag(i) and Cd(ii) hydrozanomide-based complexes with antibacterial and anticancer properties.
Article in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
A series of new Ag(i) and Cd(ii) hydrozanomide-based complexes have been prepared and studied. The synthesized compounds have undergone extensive spectroscopic and structural characterization, including F-AAS, FTIR, single crystal XRD and TGA analyses. Crystal structures of two representative complexes, 4 and 6, have revealed that the silver atom in complex 4 assumes a four-coordinate geometry with two ligands. Additionally, the stability of these complexes in DMSO has been determined using UV-vis spectroscopy. The biological activity of these metal complexes has been assessed, focusing on their antibacterial and anticancer properties against LN-229 and U87 cell lines. Among the tested compounds, silver-based complexes demonstrated significant antibacterial activity against a wide range of microorganisms. Moreover, cytotoxicity studies have shown that the metal complexes exhibit higher anticancer activity compared to their parent ligands. Notably, the Ag(i) complexes of L
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.